ライフサイエンスコーパス: calcineurin

1 oire of protein targets well beyond mTOR and calcineurin.

2 signaling pathway involving the phosphatase calcineurin.

3 by Galphai/o, novel PKC isoforms, or calcium-calcineurin.

4 x to promote its activation by AKAP-anchored calcineurin.

5 tive feedback loop mediated through CAST and calcineurin.

6 ritical for binding and inhibition of fungal calcineurin.

7 CA encodes the alpha isoform of a subunit of calcineurin.

8 m response factor and the signaling effector calcineurin.

9 d with gene and protein expression levels of calcineurin.

10 dependence of the CaM-dependent phosphatase calcineurin.

11 ia IP(3) and ryanodine receptors to activate calcineurin.

12 creased mRNA of the Nfat target regulator of calcineurin 1.

13 postnatal splicing transitions of the three calcineurin A genes, calcium-dependent phosphatases that

14 Redirected splicing of calcineurin A to the fetal isoforms in adult muscle and

15 We examined the roles of 2 homologs of Calcineurin A, CanA14F, and Pp2B in the Drosophila cardi

16 Here, we demonstrate that activating calcineurin, a calcium-dependent phosphatase, following

17 that can mediate the induction of ATF4, and calcineurin, a calcium-dependent regulator of NFAT, syne

18 Calcineurin, a conserved protein from yeast to humans, i

19 TR is dependent on CFTR dephosphorylation by calcineurin, a protein phosphatase that is upregulated b

20 ator of calcineurin (RCAN1), an inhibitor of calcineurin, a well-characterized tau phosphatase.

21 of pathological myocyte hypertrophy, despite calcineurin Aalpha expression in the same cells.

22 Overexpression of calcineurin Abeta1 in TMEM43 mutant mice or chemical GSK

23 expression of the calcineurin splice variant calcineurin Abeta1 results in GSK3beta inhibition and im

24 We have recently discovered that TCR-induced calcineurin activates DAPK1, which interacts with TSC2 v

25 Dephosphorylation of CrzA by calcineurin activates the TF, but the specific phosphory

26 gh NMDA and AMPA mediated calcium influx and calcineurin activation to then oppose further membrane d

27 arization signals, both processes relying on calcineurin activation.

28 red myocytes revealed that Ca(2+) levels and calcineurin activity associated with the CIP4 compartmen

29 aused myofibril disarray, whereas inhibiting Calcineurin activity attenuated FoxO-mediated murf1 expr

30 FAT transcription factors, and inhibition of calcineurin activity by treatment with cyclosporin A (Cs

31 Conversely, Ca(2+) levels and calcineurin activity detected by nonlocalized Forster re

32 Calcineurin activity impaired Orm2 export from the endop

33 sfer reporters were used to assay Ca(2+) and calcineurin activity in living cells.

34 te whether FKBP12 plays a role in regulating calcineurin activity in the absence of Tacrolimus.

35 Increased calcineurin activity is associated with alpha-synuclein

36 Thus, FKBP12 can endogenously regulate calcineurin activity with therapeutic implications for t

37 acrolimus is an inhibitor of the phosphatase calcineurin, an action shared with cyclosporine.

38 Calcineurin anchoring by AKAPs confers specificity to ca

39 first to identify cross-talk between Ca(2+)/calcineurin and Cdc42 signaling and to demonstrate modul

40 els appears to be independent of calmodulin, calcineurin and endocytic pathways.

41 eased cytoplasmic Ca(2+) load that activates calcineurin and induces the second phasic Drp1-dependent

42 Calcium signaling through calcineurin and its major transcription factor (TF), Crz

43 Pharmacologic or genetic inhibition of calcineurin and NFAT signaling reverses the effects of p

44 TOX is induced by calcineurin and NFAT2, and operates in a feed-forward lo

45 and tumour cell proliferation by inhibiting calcineurin and NFATc3 activation in mouse and human set

46 h selectively blocks the interaction between calcineurin and NFATc3, through computational and medici

47 this was accompanied with the activation of calcineurin and subsequent translocation of NFATc4 to th

48 a(2+)-sensitive interface between AKAP79 and calcineurin, and increases resting cellular PKA phosphor

49 2+)-dependent signaling molecules, including calcineurin, and inhibition of SOCE or calcineurin impai

50 hospholipase Cbeta, protein kinase Cepsilon, calcineurin, and phospholamban.

51 lar chaperone Hsp90, the protein phosphatase calcineurin, and the small GTPase Ras1, as well as with

52 e CDI whereas recruitment of the phosphatase calcineurin antagonizes the effect of PKA.

53 Drugs targeting calcineurin are potent antifungal agents but also pertur

54 This report implicates calcineurin as an intracellular signaling molecule respo

55 SK3beta inhibition bypassed the calreticulin/calcineurin axis and increased osteoblast output from bo

56 By creating a SC conditional KO of calcineurin B (CnB(scko)), we assessed the effects of Cn

57 neurin in ALL and observed that depletion of calcineurin B (CnB) in leukemia cells dramatically prolo

58 reens and unbiased lipidomics, we identified calcineurin B homologous protein 1 (CHP1) as a major reg

59 The families of 10 Calcineurin B-Like (CBL) calcium sensors and 26 CBL-Inte

60 with CIPK23 requires kinase activity and the calcineurin B-like binding protein CBL1.

61 for plants, it remained unknown if, and how, calcineurin B-like calcium sensors (CBLs) and CBL-intera

62 Using a genetic screen, we found that CALCINEURIN B-LIKE INTERACTING PROTEIN KINASE23 (CIPK23)

63 In this pathway, the CALCINEURIN B-LIKE10 (AtCBL10) calcium sensor interacts

64 Calcium-dependent protein kinases (CPKs) and calcineurin-B-like proteins (CBLs) can sense and transla

65 interval 1.09-2.41; P < 0.02) and the use of calcineurin-based therapy maintenance therapy (hazard ra

66 reens revealed that CEFIP interacts with the calcineurin-binding protein four and a half LIM domains

67 Mutations of the calcineurin-binding sites in the channel (PQAAAS-AQAP) d

68 Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inh

69 Further study indicated that inhibition of calcineurin by cyclosporine A or knockdown of NFATc4 usi

70 Inhibition of calcineurin by FK506 results in an increase in the net p

71 Calcineurin can be inhibited with Tacrolimus through the

72 and recent literature has demonstrated that calcineurin can regulate autophagy via dephosphorylation

73 lin-dependent protein kinase II (CaMKII) and calcineurin (CaN) both bind open calmodulin, favoring Lo

74 ganglion neurons, becomes dysfunctional upon calcineurin (CaN) inhibition.

75 Calcineurin (CaN) phosphatase signaling is regulated by

76 we investigated the role of the phosphatase calcineurin (CaN) using electrophysiological, molecular,

77 The calcium-dependent protein phosphatase, calcineurin (CaN), has been implicated in both the conso

78 rylation by the Ca(2+)-dependent phosphatase calcineurin (CaN).

79 2+)/calmodulin-dependent protein phosphatase calcineurin (CaN, PP2B, and PPP3).

80 Therefore, the calcineurin cascade is an attractive target in drug deve

81 Here we report the crystal structures of calcineurin catalytic (CnA) and regulatory (CnB) subunit

82 ained paradox is how the beta isoform of the calcineurin catalytic A-subunit (CaNAbeta) is required f

83 Variants near the calcineurin catalytic subunit gamma gene PPP3CC and the

84 We found that knockdown of these calcineurin catalytic subunits caused cardiac restrictio

85 ng pathway (MtRS) involving Ca(+2)-sensitive Calcineurin (Cn) activation as an immediate upstream eve

86 Calcineurin (Cn) is a calcium-activated serine/threonine

87 RBLE-pep, we systematically probe binding of calcineurin (CN), a conserved protein phosphatase essent

88 ng the calcium-activated Ser/Thr phosphatase calcineurin (CN), and its downstream target nuclear fact

89 sis, is regulated by the Ser/Thr phosphatase calcineurin (CN).

90 overy to elucidate the regulatory network of calcineurin (CN)/PP2B, the Ca(2+)-activated phosphatase

91 PPP3R1 is the regulatory subunit of the calcineurin complex.

92 Fungal calcineurin complexes are similar to the mammalian compl

93 In eukaryotic microbial pathogens, calcineurin controls essential virulence pathways, such

94 Rcr1, but not Rcr2, is up-regulated via the calcineurin/Crz1 signaling pathway.

95 kinase activation, Ca(2+) mobilization, and calcineurin-dependent activation of NFAT, the master tra

96 This was caused by calcineurin-dependent dephosphorylation of Orm2, a repre

97 K(+) current to the resting state after the calcineurin-dependent dephosphorylation of TRESK.

98 on of glial Ca(2+) causes hyperactivation of calcineurin-dependent endocytosis and accumulation of ea

99 d that CEFIP overexpression further enhances calcineurin-dependent hypertrophic signal transduction,

100 We earlier reported that the Ca(2+)- and calcineurin-dependent MtRS induces macrophage differenti

101 induction of the IP-10 gene was mediated by calcineurin-dependent NFAT signaling in pancreatic beta-

102 We show that FKBP12 profoundly affects the calcineurin-dependent phosphoproteome, promoting the dep

103 increase of cholinergic synapses and a TAX-6/calcineurin-dependent reduction of GABA synapses.

104 The TRESK component confers calcineurin-dependent regulation to the heterodimer and

105 the in vivo relevance of HDAC1 and identify calcineurin-dependent serine dephosphorylation as the si

106 in the activated state of TRESK (i.e., after calcineurin-dependent stimulation) than in the resting s

107 al context for this regulation and show that calcineurin dephosphorylates and positively regulates Rg

108 at the calcium-activated protein phosphatase calcineurin dephosphorylates Hoxb13 at serine-204, resul

109 2 mutant that is defective for regulation by calcineurin display increased gene expression in respons

110 Whether calcineurin/FKBP12 represents a native physiologically r

111 m/calmodulin-dependent phosphatase 2B (PP2B, calcineurin) focuses and insulates termination of local

112 ggest that leukemia cells are dependent upon calcineurin for immune evasion by restricting the regula

113 disrupts myofibril integrity by activating a Calcineurin-FoxO-MuRF1-proteosome signaling pathway.

114 in anchoring by AKAPs confers specificity to calcineurin function in the cardiac myocyte.

115 Although WNT signaling and calcineurin have been implicated separately in muscle re

116 uding calcineurin, and inhibition of SOCE or calcineurin impairs antigen-dependent T cell proliferati

117 activating the calcium-activated phosphatase calcineurin in a Ca(2+)/calmodulin-dependent manner, pre

118 We sought to understand the role of calcineurin in ALL and observed that depletion of calcin

119 Our results suggest a key role for calcineurin in cardiac remodeling during long-term hypox

120 iscuss the current knowledge on the roles of calcineurin in eukaryotic microbial pathogens, focusing

121 which is dephosphorylated by the phosphatase calcineurin in MG cells.

122 SNO-Calcineurin in mutant led to a significant increase of p

123 However, little is known about the role of calcineurin in promyelinating SCs after birth.

124 stic understanding of the role of endogenous calcineurin in regulating synaptic plasticity and nocice

125 Finally, this paper clarifies the role of calcineurin in Schwann cells and myelination.

126 In contrast, we did find a unique role for calcineurin in SCs after nerve injury.

127 oupling while not stimulating hypertrophy by calcineurin in the normal heart.

128 rast, the mutations of the target residue of calcineurin in TRESK, S264A, and S264E prevented the eff

129 s in a feed-forward loop in which it becomes calcineurin-independent and sustained in T(ex) cells.

130 of TRESK at the regulatory residue S264 in a calcineurin-independent manner.

131 efined may represent novel targets to reduce calcineurin induced nephrotoxicity.

132 uclear calpain 1, by cleaving and activating calcineurin, induces NFIB dephosphorylation.

133 functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treat

134 We showed that calcineurin inhibition enhances physical interaction bet

135 Although calcineurin inhibition increases NMDAR activity in the s

136 Accordingly, in vivo calcineurin inhibition leads the most self-reactive naiv

137 activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both

138 Interestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an imm

139 d the association of optimal-dose mTORi with calcineurin inhibitor (CNI) have excluded hypersensitize

140 d the association of optimal-dose mTORi with Calcineurin Inhibitor (CNI) have excluded hypersensitize

141 ipients with renal dysfunction attributed to calcineurin inhibitor (CNI) nephrotoxicity.

142 As conversion from calcineurin inhibitor (CNI) to sirolimus (SRL), an mTOR-

143 -1a) cells, which were highly sensitive to a calcineurin inhibitor (CNI), while co-stimulation of TLR

144 kidney (SPK) recipients were randomized to a calcineurin inhibitor (CNI)-based immunosuppressive regi

145 dy sought to examine whether conversion from calcineurin inhibitor (CNI)-based to SRL-based IS was as

146 A calcineurin inhibitor (CNI)-free immunosuppressive regim

147 with poor renal response when switching to a calcineurin inhibitor (CNI)-lowered or CNI-free immunosu

148 mbination of mycophenolates (MMF/MPA) with a calcineurin inhibitor (CNI).

149 ) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate).

150 ansplant Everolimus De Novo Study With Early Calcineurin Inhibitor Avoidance trial, where de novo HTx

151 tics and concurrent graft function and blood calcineurin inhibitor concentration.

152 clinically available, we recommend to adjust calcineurin inhibitor dose according to whole blood trou

153 If nephrotoxicity is suspected, the calcineurin inhibitor dose should be reduced.

154 nsistently, AMPA receptor antagonist CNQX or calcineurin inhibitor FK506 abolished the S-SCAM overexp

155 to analyze this association exploring median calcineurin inhibitor levels and intrapatient variabilit

156 ment of dnDSA in 69 LT patients who received calcineurin inhibitor monotherapy and were enrolled in t

157 inhibition of cathepsin K, or treatment with calcineurin inhibitor rescued cells from high-glucose tr

158 Treatment with sirolimus, but not the calcineurin inhibitor tacrolimus, at levels routinely ac

159 ive patients were treated with conversion of calcineurin inhibitor to mammalian target of rapamycin i

160 As conversion from calcineurin inhibitor to sirolimus (SRL), a mechanistic

161 mozygotes were less likely to report topical calcineurin inhibitor use (OR, 0.16; 95% CI, 0.06-0.42),

162 nt included antimetabolite withdrawal (68%), calcineurin inhibitor withdrawal (23%), hydroxychloroqui

163 herapy (steroids, mycophenolate mofetil, and calcineurin inhibitor).

164 4s with the immunosuppressant cyclosporin, a calcineurin inhibitor, robustly inhibited HIV-1 reactiva

165 th the highest remission rates achieved with calcineurin inhibitor-based protocols.

166 alpha2delta-1 is essential for calcineurin inhibitor-induced aberrant activation of pre

167 Calcineurin inhibitor-induced neurotoxicity (CIIN) is a

168 ting alpha2delta-1-NMDAR interaction reduces calcineurin inhibitor-induced pain hypersensitivity.

169 neurons or alpha2delta-1 KO also attenuates calcineurin inhibitor-induced pain hypersensitivity.

170 re pain in patients, commonly referred to as calcineurin inhibitor-induced pain syndrome (CIPS).

171 cate that alpha2delta-1-bound NMDARs mediate calcineurin inhibitor-induced tonic activation of presyn

172 Altogether, these results might suggest that calcineurin inhibitor-induced tubular SNAI1 protein cyto

173 ly evident in biopsy specimens obtained from calcineurin inhibitor-treated patients, which might be b

174 c anti-inflammatory drug Tacrolimus (TAC), a calcineurin inhibitor.

175 28-CD80/86 costimulatory pathway, allows for calcineurin-inhibitor free immunosuppressive therapy in

176 ors probably reduced skin cancer compared to calcineurin inhibitors (12 trials, 2225 participants, RR

177 and safety of belatacept when converted from calcineurin inhibitors (CNI) in HLA-sensitized (HS) kidn

178 and safety of belatacept when converted from calcineurin inhibitors (CNI) in HLA-sensitized kidney tr

179 such as polyomavirus-associated nephropathy, calcineurin inhibitors (CNI), and genetic factors.

180 The long-term use of calcineurin inhibitors (CNIs) after liver transplantatio

181 Calcineurin inhibitors (CNIs) are among the most effecti

182 Maintenance steroids and calcineurin inhibitors (CNIs) at discharge were associat

183 pressive regimen mostly relies on converting calcineurin inhibitors (CNIs) into EVL.

184 been partially attributed to treatment with calcineurin inhibitors (CNIs).

185 mplementation of this strategy to avoid both calcineurin inhibitors and corticosteroids at this time.

186 mitigate early rejection risk while limiting calcineurin inhibitors and corticosteroids.

187 rity and responsiveness to topical steroids, calcineurin inhibitors and step-up treatment.

188 es are limited by toxicities associated with calcineurin inhibitors and steroids.

189 Nephrotoxicity of calcineurin inhibitors and uncontrolled effector functio

190 The antitumor effects of calcineurin inhibitors are associated with the reduced e

191 e development of CIPS.SIGNIFICANCE STATEMENT Calcineurin inhibitors are immunosuppressants used to pr

192 an HEart transplant De-novo stUdy with earLy calcineurin inhibitors avoidancE trial was a prospective

193 an HEart transplant De-novo stUdy with earLy calcineurin inhibitors avoidancE trial was the first ran

194 Until measurement of unbound fraction of calcineurin inhibitors becomes clinically available, we

195 understanding the association between early calcineurin inhibitors exposure post-liver transplantati

196 Likewise, alternatives to calcineurin inhibitors have been investigated as a strat

197 Calcineurin inhibitors have shown evidence to promote ca

198 Calcineurin inhibitors induce nephrotoxicity through poo

199 Use of calcineurin inhibitors is associated with HTN.

200 Topical calcineurin inhibitors may be used in steroid-dependent/

201 atacept, induction agents, and withdrawal of calcineurin inhibitors or corticosteroids).

202 Calcineurin inhibitors successfully control rejection of

203 CKD was related to calcineurin inhibitors toxicity in 38 (84.4%) cases.

204 Antimetabolites +/- calcineurin inhibitors were held or reduced.

205 ical corticosteroids with or without topical calcineurin inhibitors where inadvisable for topical cor

206 th either topical corticosteroids or topical calcineurin inhibitors) in mild AD cases or the preventi

207 r monoclonal antibodies, 28% did not receive calcineurin inhibitors, and 36% did not receive steroids

208 opical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics.

209 sted of plasma exchanges (PE), high doses of calcineurin inhibitors, and steroids.

210 For decades, GVHD prophylaxis has included calcineurin inhibitors, despite their incomplete efficac

211 llograft rejection without using steroids or calcineurin inhibitors, enriches for naive cells suscept

212 egimes (azathioprine, mycophenolate mofetil, calcineurin inhibitors, mammalian target of rapamycin [m

213 equired the use of topical steroids, topical calcineurin inhibitors, or other medications within the

214 Calcineurin inhibitors, such as tacrolimus (FK506) and c

215 g all patients that had discontinued topical calcineurin inhibitors, those with the rs1898671 single-

216 rapidly released Gal-3, which was blocked by calcineurin inhibitors.

217 nosuppressive agents were antimetabolites or calcineurin inhibitors.

218 nteract with immunosuppressive drugs such as calcineurin inhibitors.

219 The Ca(2+)/calmodulin-dependent phosphatase calcineurin is a key regulator of cardiac myocyte hypert

220 ous Ca(2+) /calmodulin-dependent phosphatase calcineurin is a key regulator of pathological cardiac h

221 Calcineurin is a phosphatase whose primary targets in T

222 Calcineurin is an essential Ca(2+)-dependent phosphatase

223 Calcineurin is cleaved and activated by calpain protease

224 Calcineurin is cleaved and thereby activated by calpain

225 Calcineurin is important for fungal virulence and a pote

226 Calcineurin is known to be critical in cardiac hypertrop

227 Together, our data indicate that calcineurin is not essential for myelination but has a n

228 Calcineurin is targeted to diverse intracellular compart

229 onstrate a previously unknown specificity of calcineurin isoforms as well as the broader impact of al

230 n cue-induced reinstatement, suggesting that calcineurin may be a potential therapeutic target for re

231 the nucleus 3 d after crush, suggesting that calcineurin may regulate autophagy in SCs via TFEB activ

232 rom endoplasmic reticulum stores, leading to calcineurin-mediated dephosphorylation and activation of

233 ut mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT.

234 ssed at P0, and combined Foxc2 deletion with calcineurin-Nfat inhibition disrupted early Prox1(hi) en

235 ricytes in APOE4-mediated CAA and highlights calcineurin-NFAT signaling as a therapeutic target in CA

236 as inositol phosphate-mediated signaling and calcineurin-NFAT signaling cascade as important biologic

237 ricytes of APOE4 carriers, and inhibition of calcineurin-NFAT signaling reduces APOE4-associated CAA

238 and its knockdown repressed hypertrophy and calcineurin/NFAT activity.

239 neage where it mediates proper regulation of calcineurin/NFAT signaling and COX-2 expression.

240 juvenile islets, Ex-4 induced expression of calcineurin/NFAT signaling components as well as target

241 -regulation of NFAT-c2, reflecting increased calcineurin/NFAT signaling in myocyte hypertrophy.

242 K and those associated with Ca(2+) handling, calcineurin/NFAT signaling, insulin signaling, cardiac a

243 mechanistic investigation revealed impaired calcineurin/NFATc1 activation and decreased COX-2 expres

244 l experiments revealed that dysregulation of calcineurin-nuclear factor of activated T cells (NFAT) s

245 w that the mitogenic effect of Ex-4 requires calcineurin/nuclear factor of activated T cells (NFAT) s

246 Calcineurin/nuclear factor of activated T cells (Nfat) s

247 eted by Cdks during the cell cycle, and that calcineurin opposes Fus3 to activate Rga2 and decrease C

248 structural responses to NPY or CRF required calcineurin or CaMKII, respectively.

249 t groups, older age, less physical activity, calcineurin or mammalian target of rapamycin inhibitor-b

250 Mutants lacking calcineurin, or its client CrzA, displayed normal alkali

251 by decreased intracellular Ca(2+) levels via calcineurin, p38 mitogen-activated protein kinase (MAPK)

252 rate that calcium-mediated activation of the calcineurin pathway acts as a rheostat to shape both the

253 cells enhanced downstream factors in the BCR-calcineurin pathway, including a nuclear factor of activ

254 osphorylation in the brain through the RCAN1-calcineurin pathway.

255 ds on the NFI phosphorylation state and that calcineurin phosphatase dephosphorylates and activates N

256 the IDR results in CR defects and abolishes calcineurin phosphatase localization to the CR.

257 epsilon The effect of PKC is not mediated by calcineurin phosphatase, which is known to evoke the cal

258 These results suggest that, in addition to calcineurin, PKC regulates TRESK by changing the phospho

259 , and the control of Brg1 phosphorylation by calcineurin, PKCbeta1, and p38 regulates the transition

260 Male mice lacking sperm-specific calcineurin (PP2B), a calcium regulated phosphatase, in

261 s based on an isoform-specific mechanism for calcineurin protein-protein interaction and localization

262 A2M gene network that includes regulator of calcineurin (RCAN1), an inhibitor of calcineurin, a well

263 We here report that SOCE and calcineurin regulate cell cycle entry of quiescent T cel

264 Calcineurin regulates Dig2 and Rod1/Art4 to inhibit mati

265 Furthermore, we show that the enzyme calcineurin regulates Kv2.1 ion channel clustering statu

266 The enzyme calcineurin regulates Kv2.1 ion channel declustering.

267 ort (including the alpha4 nAChR subunit, the calcineurin regulator RCAN3, and KIF1C of the kinesin fa

268 , mechanistic target of rapamycin (mTOR) and calcineurin, respectively.

269 We also show that the calcineurin-responsive transcription factor Crz1 undergo

270 by the protein phosphatases PP-1 and PP-2B (calcineurin) reverses this effect.

271 n (FDA)-approved compound Tacrolimus, blocks calcineurin's activity toward those proteins and protect

272 ors against the upstream protein phosphatase calcineurin should be effective for prevention/treatment

273 intracellular compartmentation of Ca(2+) and calcineurin signal transduction.

274 ene delivery in the mouse were used to study calcineurin signaling after transverse aortic constricti

275 The calcineurin signaling cascade is one of the major pathwa

276 lin-1 Type III has been proposed to activate calcineurin signaling in immature SCs to initiate differ

277 CNI103 specifically inhibited calcineurin signaling in vitro and in vivo and exhibited

278 Calcineurin signaling is a key pathway underlying fibrob

279 cross-talk between NFI and the CAST/calpain/calcineurin signaling pathway in MG cells.

280 he mechanisms conferring this selectivity in calcineurin signaling should reveal new strategies for t

281 N-methyl-D-aspartate receptors coupled with calcineurin signaling, induces t-LTD which is sensitive

282 pression of the receptor TGF-betaRII through calcineurin signaling.

283 chy governing alkaline tolerance circumvents calcineurin signalling.

284 Targeting of calcineurin 'signalosomes' may provide a rationale for i

285 ficial effect, whereas overexpression of the calcineurin splice variant calcineurin Abeta1 results in

286 eractivation, which leads to Hsp90-dependent calcineurin stabilization and thereby increased azole re

287 l antifungal target, but compounds targeting calcineurin, such as FK506, are immunosuppressive.

288 relaxation, promotes nuclear localization of calcineurin target Nfatc3, and/or affects expression of

289 Calcineurin, the conserved Ca(2+)/calmodulin-activated p

290 indicating that NFI activity is regulated by calcineurin, these results provide a foundation for furt

291 ls must exist to permit catalytically active calcineurin to function during epididymal sperm maturati

292 which signals danger via TRPV4, calcium, and calcineurin to initiate allergic sensitization.

293 tory cross-talk between the ESCRT machinery, calcineurin/TORC2 signaling, and the EGAD pathway import

294 the Ca(2+)/calmodulin-dependent phosphatase calcineurin toward nuclear factor of activated T-cells (

295 Here we found that calcineurin was recruited to the T cell antigen receptor

296 Calreticulin activates calcineurin, which dephosphorylates and induces the nucl

297 Ca(2+) influx resulting in the activation of calcineurin, which in turn activates TFEB, the master re

298 w that TPC-released Ca(2+) rapidly activates calcineurin, which in turn dephosphorylates and activate

299 he functional interaction between FKBP12 and calcineurin, with low doses of the Food and Drug Adminis

300 ich triggers a calcium flux signaled through calcineurin within club cells of the bronchioles, inciti